Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC (HKMPF) Financial Performance & Income Statement Overview
Explore the financials of Hikma Pharmaceuticals PLC (HKMPF), including yearly and quarterly data on income, cash flow, and balance sheets.
Hikma Pharmaceuticals PLC (HKMPF) Income Statement & Financial Overview
Review Hikma Pharmaceuticals PLC HKMPF income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $1.56B | $1.57B | $1.47B | $1.47B |
| Cost of Revenue | $899.00M | $813.00M | $833.08M | $758.59M |
| Gross Profit | $659.00M | $756.00M | $638.02M | $710.21M |
| Gross Profit Ratio | $0.42 | $0.48 | $0.43 | $0.48 |
| R&D Expenses | $80.00M | $61.00M | $86.36M | $65.87M |
| SG&A Expenses | $382.00M | $280.00M | $424.67M | $267.62M |
| Operating Expenses | $398.00M | $405.00M | $510.009M | $352.02M |
| Total Costs & Expenses | $1.30B | $1.22B | $1.34B | $1.11B |
| Interest Income | $0.00 | $40.00M | $4.06M | $3.09M |
| Interest Expense | $0.00 | $0.00 | $43.69M | $45.29M |
| Depreciation & Amortization | $82.00M | $97.00M | $96.52M | $98.81M |
| EBITDA | $288.00M | $499.00M | $219.45M | $352.02M |
| EBITDA Ratio | $0.18 | $0.32 | $0.15 | $0.31 |
| Operating Income | $261.00M | $351.00M | $128.01M | $358.19M |
| Operating Income Ratio | $0.17 | $0.22 | $0.09 | $0.24 |
| Other Income/Expenses (Net) | -$94.00M | -$63.00M | -$47.75M | -$37.08M |
| Income Before Tax | $167.00M | $288.00M | $80.26M | $207.92M |
| Income Before Tax Ratio | $0.11 | $0.18 | $0.05 | $0.14 |
| Income Tax Expense | $34.00M | $59.00M | $18.29M | $73.08M |
| Net Income | $133.00M | $226.00M | $59.94M | $134.84M |
| Net Income Ratio | $0.09 | $0.14 | $0.04 | $0.09 |
| EPS | $0.60 | $1.01 | $0.27 | $0.61 |
| Diluted EPS | $0.60 | $1.01 | $0.27 | $0.61 |
| Weighted Avg Shares Outstanding | $221.85M | $223.76M | $220.56M | $221.00M |
| Weighted Avg Shares Outstanding (Diluted) | $223.22M | $223.76M | $223.19M | $222.00M |
Financial performance has remained strong, with revenue growing from $1.47B in Q2 2023 to $1.56B in Q4 2024. Gross profit continued to perform well, with margins at 42% in the latest quarter. Operating income reached $261.00M in Q4 2024, holding a steady 17% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $288.00M. Net income dropped to $133.00M, keeping EPS at $0.60. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan